Ocular Surface TumorsNCT06808126
Evaluation of Ocular Surface Tumors Using Anterior Segment Optical Coherence Tomography (OCT)
An observational study of Ocular Surface Tumors, run by Assiut University.
Trial summary
optical coherence tomography (OCT) can scan a range of ocular tissues and take high-resolution image sections during ophthalmic examination.. and recommended as a rapid, informative and quite reliable method of examination to differentiate benign from malignant ocular surface tumors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ocular Surface Tumors
- How many people
- 58 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2025to 1 May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients presented with ocular surface lesion suspected to be neoplastic
Who may be able to join
- all patients presented with ocular surface lesion suspected to be neoplastic
Who cannot join
- all patients presented with ocular surface lesion proved by pathology not to be neoplastic
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
optical coherence tomography (OCT) can scan a range of ocular tissues and take high-resolution image sections during ophthalmic examination..
and recommended as a rapid, informative and quite reliable method of examination to differentiate benign from malignant ocular surface tumors.
Read more
The conjunctiva is an anatomical site with a prominent risk of squamous cell carcinoma development, which is a unique biological behavior. The superficial lesion with significant epithelial cell growth usually displays unique data, contributing to unusual ocular tumors.
Anterior segment optical coherence tomography (AS-OCT), as a noninvasive, high-resolution imaging technique, provides crucial morphological and anatomical information in ocular surface tumors via visualizing the layer structure of the cornea and anterior segment, qualifying tumor morphology, and quantifying thickness and extension. AS-OCT can provide valuable information for helping in clinical diagnoses, differential diagnoses, prognoses, and evaluating responses to treatments as a significant imaging tool in ocular surface tumors.
The correct diagnosis and classification of ocular surface tumors are crucial aspects of their proper management.
the aim of the study • To evaluate the imaging characteristics of ocular surface tumors on high-resolution anterior segment optical coherence tomography (ASOCT).
Read the detailed description
optical coherence tomography (OCT) can scan a range of ocular tissues and take high-resolution image sections during ophthalmic examination..
and recommended as a rapid, informative and quite reliable method of examination to differentiate benign from malignant ocular surface tumors.
The conjunctiva is an anatomical site with a prominent risk of squamous cell carcinoma development, which is a unique biological behavior. The superficial lesion with significant epithelial cell growth usually displays unique data, contributing to unusual ocular tumors.
Anterior segment optical coherence tomography (AS-OCT), as a noninvasive, high-resolution imaging technique, provides crucial morphological and anatomical information in ocular surface tumors via visualizing the layer structure of the cornea and anterior segment, qualifying tumor morphology, and quantifying thickness and extension. AS-OCT can provide valuable information for helping in clinical diagnoses, differential diagnoses, prognoses, and evaluating responses to treatments as a significant imaging tool in ocular surface tumors.
The correct diagnosis and classification of ocular surface tumors are crucial aspects of their proper management.
the aim of the study • To evaluate the imaging characteristics of ocular surface tumors on high-resolution anterior segment optical coherence tomography (ASOCT).
- Conditions
- Ocular Surface Tumors
- Keywords
- Optical Coherence Tomography
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Ocular Surface Tumors | patients presented with ocular surface lesion suspected to be neoplastic |
What is being measured
The primary outcome is the main question the study is designed to answer.
the accuracy of oct
the accuracy of oct in diagnosis of Ocular Surface Tumors
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2025
- Study start1 Mar 2025 (estimated)
- Primary completion1 Mar 2026 (estimated)
- Study completion1 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ocular Surface TumorsStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 58 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amira Mohamed Abdelrahman Gebaly, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06808126
- Sponsor's protocol ID
- Ocular Surface Tumors by OCT
- Status last verified
- Jan 2025
- First submitted
- 29 Jan 2025
- Last updated
- 5 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Ocular Surface Tumors Using Anterior Segment Optical Coherence Tomography (OCT)
- ClinicalTrials.gov ID
- NCT06808126
- Acronym / sponsor ID
- Ocular Surface Tumors by OCT
- Conditions
- Ocular Surface Tumors
- Keywords
- Optical Coherence Tomography
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 58 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Mar 2025 (estimated)
- Primary completion
- 1 Mar 2026 (estimated)
- Study completion
- 1 May 2026 (estimated)
- First posted
- 5 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
optical coherence tomography (OCT) can scan a range of ocular tissues and take high-resolution image sections during ophthalmic examination..
and recommended as a rapid, informative and quite reliable method of examination to differentiate benign from malignant ocular surface tumors.
The conjunctiva is an anatomical site with a prominent risk of squamous cell carcinoma development, which is a unique biological behavior. The superficial lesion with significant epithelial cell growth usually displays unique data, contributing to unusual ocular tumors.
Anterior segment optical coherence tomography (AS-OCT), as a noninvasive, high-resolution imaging technique, provides crucial morphological and anatomical information in ocular surface tumors via visualizing the layer structure of the cornea and anterior segment, qualifying tumor morphology, and quantifying thickness and extension. AS-OCT can provide valuable information for helping in clinical diagnoses, differential diagnoses, prognoses, and evaluating responses to treatments as a significant imaging tool in ocular surface tumors.
The correct diagnosis and classification of ocular surface tumors are crucial aspects of their proper management.
the aim of the study • To evaluate the imaging characteristics of ocular surface tumors on high-resolution anterior segment optical coherence tomography (ASOCT).
Detailed description
optical coherence tomography (OCT) can scan a range of ocular tissues and take high-resolution image sections during ophthalmic examination..
and recommended as a rapid, informative and quite reliable method of examination to differentiate benign from malignant ocular surface tumors.
The conjunctiva is an anatomical site with a prominent risk of squamous cell carcinoma development, which is a unique biological behavior. The superficial lesion with significant epithelial cell growth usually displays unique data, contributing to unusual ocular tumors.
Anterior segment optical coherence tomography (AS-OCT), as a noninvasive, high-resolution imaging technique, provides crucial morphological and anatomical information in ocular surface tumors via visualizing the layer structure of the cornea and anterior segment, qualifying tumor morphology, and quantifying thickness and extension. AS-OCT can provide valuable information for helping in clinical diagnoses, differential diagnoses, prognoses, and evaluating responses to treatments as a significant imaging tool in ocular surface tumors.
The correct diagnosis and classification of ocular surface tumors are crucial aspects of their proper management.
the aim of the study • To evaluate the imaging characteristics of ocular surface tumors on high-resolution anterior segment optical coherence tomography (ASOCT).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Ocular Surface Tumors | – | –patients presented with ocular surface lesion suspected to be neoplastic |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients presented with ocular surface lesion suspected to be neoplastic
Key inclusion criteria (1 listed)
- all patients presented with ocular surface lesion suspected to be neoplastic
Key exclusion criteria (1 listed)
- all patients presented with ocular surface lesion proved by pathology not to be neoplastic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
the accuracy of oct
Time frame: baseline
the accuracy of oct in diagnosis of Ocular Surface Tumors
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Ocular Surface Tumors
Recruiting
Feasibility Study of Ocular Surface Squamous Neoplasia Surgical Excision in People Living With HIV in Sub-Saharan Africa
Ocular Surface Squamous Neoplasia, HPV
RecruitingObservational study
Ocular Complications From Cancer Therapy - Patient Registry and Biobank
Graft Versus Host Disease in Eye, Ocular Complications
RecruitingObservational study
Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers
Ocular Sebaceous Carcinoma, Ocular Basal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Ocular Surface Tumors, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amira Mohamed Abdelrahman Gebaly, residant doctor (+201070445825, amira.moh1998@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the accuracy of oct (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2025.